ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,807 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentSchlierenLimmaTech Biologics AG
LimmaTech Biologics AG Logo
Verified· 4 sources

LimmaTech Biologics AG

Summary

About the company

The core activity of LimmaTech Biologics AG is the development and manufacture of vaccines and other biotechnological products, particularly in the field of infectious diseases. The company focuses on the development of a proprietary vaccine platform and has a pipeline of products in various stages of development.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Pharmaceutical Industry
✓ Offered5
Vaccine development
Development of vaccine candidates against antimicrobial-resistant pathogens and bacterial infections, based on multivalent vaccine technology and pathogen-specific approaches.
Proprietary vaccine platform
Proprietary multivalent vaccine technology for developing candidates with multiple immunogenic antigens in a scalable single step, including E. coli-based and self-adjuvanting approaches.
Bioconjugation technology
In vivo enzyme-based bioconjugation for the precise conjugation of pathogen glycans with immunogenic proteins, to shorten development time and improve safety and cost structure.
Toxoid vaccine technology
Toxoid-based approach for developing vaccine candidates against bacterial toxins, with a clinical program against Staphylococcus aureus.
Clinical vaccine programs
Clinical development of vaccine candidates, including Shigella4V (S4V) and LBT-SA7, in Phase I/II and, respectively, Phase I studies.
Reviews

Aggregated rating

Aggregated rating
4.7
of 5

Aggregated from 3 reviews across all connected sources

Sources
GGoogle4.73
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Press

Media

May 28, 2026Media
LimmaTech Biologics wird von Lilly für bis zu 780 Millionen US-Dollar übernommen
moneycab.com
May 27, 2026Media
Lilly to acquire LimmaTech Biologics for up to USD 780 million
startupticker.ch
May 27, 2026Media
Eli Lilly kauft LimmaTech Biologics für bis zu 780 Millionen Dollar
punkt4.info
February 2, 2024Media
New investment brings LimmaTech’s series A to CHF 40 million
startupticker.ch

Knowledge

No knowledge articles yet

Once LimmaTech Biologics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

LimmaTech Biologics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank LimmaTech Biologics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of LimmaTech Biologics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Grabenstrasse 3
8952 Schlieren
Opening hours
Mon
08:30 - 17:00
Tue
08:30 - 17:00
Wed
08:30 - 17:00
Thu
08:30 - 17:00
Fri
08:30 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-354.125.957
Founded
2015 · 11 years
Last commercial register change
May 18, 2026
Employees
51 to 100

Similar companies

AH
A. Heim GmbH
Fehraltorf
BE
BRO Engineering GmbH
Dietikon
BE
Bosshard Elektronik
Wolfhausen
BS
Bota Systems AG
Zurich